Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Soligenix has received a Hong Kong patent which addresses its Lipid Polymer Micelle (LPM) technology for the improved oral delivery of drugs.
Subscribe to our email newsletter
The issued Hong Kong patent, HK 1071054, entitled ‘Stabilized Reverse Micelle Compositions and Uses Thereof’ covers lipid structures that promote the intestinal absorption of peptides and other sensitive drugs that cannot otherwise be given orally.
Christopher Schaber, president and CEO of Soligenix, said: “The issuance of the Hong Kong patent for LPM further demonstrates the novelty of this drug delivery system and the preclinical results clearly show that it is a competitive system for oral delivery of drugs, especially those biotechnology products derived from synthetic peptide chemistry or recombinant DNA.
“We also believe that the LPM system will be applicable to a large number of water-soluble drugs including peptides that are poorly permeable, resulting in increased patient compliance and safety.”
The issuance of this patent in Hong Kong follows the issuance of the same patent in Europe in 2009.